Contribute Try STAT+ Today

As concerns persist over the safety of medicines made overseas, the Food and Drug Administration recently touted data showing the number of facilities inspected in foreign countries had increased 20% over the most recent five-year period.

Specifically, the agency inspected 993 foreign plants in fiscal year 2014 compared with 1,245 in fiscal year 2018. At the same time, though, the FDA inspected fewer domestic facilities during that period — 1,869 versus 1,662, which amounts to a 12.5% drop.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.